(Reuters) – Novavax said on Monday it was “encouraged” by the broad availability of its updated COVID-19 vaccine being rolled out in the U.S., days after rival Pfizer slashed its full-year revenue forecast.
“It is too soon to evaluate U.S. vaccination rates given that vaccinations will continue in the coming weeks,” Novavax added.
Shares of vaccine maker Novavax and rival Moderna were down 6% to 7% after Pfizer on Friday flagged concerns on lower-than-expected sales of its COVID-19 vaccine and treatment.
Novavax also said it continues to work in close partnership with the European Medicines Agency (EMA), after the regulator delayed a decision to give approval for the company’s variant-tailored COVID-19 shot.
The company will provide an update on its upcoming third-quarter earnings in early November 2023.
(Reporting by Khushi Mandowara in Bengaluru; Editing by Devika Syamnath)
